New Delhi, Apr 25 (PTI) Drug maker Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat certain eye conditions.

The company has received approval from the US Food and Drug Administration (USFDA) to market Etabonate Ophthalmic Suspension, the Mumbai-based drug maker said in a statement.

Also Read | What Is Ayushman Bharat Yojana and How To Register?.

The company's product is the generic equivalent of Bausch & Lomb Inc's Lotemax ophthalmic suspension (0.5 per cent), it added.

Loteprednol Etabonate ophthalmic suspension, 0.5 per cent, is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

Also Read | Hindustan Unilever Drops 'Health Food Drinks' Label From Horlicks, Rebrands It As 'Functional Nutritional Drink'.

As per the IQVIA MAT data, the product had estimated annual sales of USD 59 million in the US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)